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Table S1. In- and exclusion criteria. 
Inclusion Criteria Exclusion Criteria 
- Presentation in cardio-oncology before start of anti-cancer 
therapy 
- Prior cancerous condition with anti-cancer 
therapy 
- Presentation in cardio-oncology for a follow-up routine  
Table S2. Applied anti-tumor therapies. 
Applied Anti-Tumor Therapy % of the Patients 
Anthracyclines (%) 27% 
 Doxorubicin (mean dose (mg/m2)) 209 
 Epirubicin (mean dose (mg/m2)) 318 
 Combination therapy with alkylating agents 92% 
Antimicrotubule agents (%) 14% 
Platin-containing therapies (%) 4% 
Antimetabolites (%) 1% 
Topoisomerase II inhibitors (%) 13% 
Tyrosine kinase inhibitors (%) 3% 
Immune checkpoint inhibitors (%) 41% 
BRAF/MEK inhibitors (%) 7% 
Anti-Her2 compounds (%) 4% 
Others (%) 16% 
 
